Retail Investors in Jiangsu Bioperfectus Technologies Co., Ltd. (SHSE:688399) Are Its Biggest Bettors, and Their Bets Paid off as Stock Gained 11% Last Week

Key Insights Significant control over Jiangsu Bioperfectus Technologies by retail investors implies that the general public has more power to influence management and governance-related decisions Th

Simply Wall StApr 30 14:20

Shuoshi Biotech (688399.SH): Net profit of 40.68 million yuan in the first quarter

Gelonghui, April 26 | Shuoshi Biotech (688399.SH) released its report for the first quarter of 2024. During the reporting period, it achieved revenue of 91.194 million yuan, a year-on-year decrease of 3.12%. Net profit attributable to shareholders of listed companies was RMB 40.68 million. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was $148.741 million.

Gelonghui FinanceApr 26 19:00

Shuoshi Biotech (688399.SH) announced 2023 annual results with a net loss of 374 million yuan, which changed from profit to loss year-on-year

Shuoshi Biotech (688399.SH) disclosed its 2023 annual report. The company achieved operating income of 4 during the reporting period...

Zhitong FinanceApr 26 18:38

Express News | Shuoshi Biotech's hypersensitive HBV nucleic acid detection reagent was approved for marketing

BreakingsMar 22 13:58

Shuoshi Biotech (688399.SH) obtained a medical device registration certificate

Zhitong Finance App News, Shuoshi Biotech (688399.SH) issued an announcement. The company recently received a medical device registration certificate (in vitro diagnostic reagent) issued by the State Drug Administration. The product name is hepatitis B virus nucleic acid detection kit (fluorescence PCR method).

Zhitong FinanceMar 21 18:04

Express News | Shuoshi Biotech: Hepatitis B virus nucleic acid detection kit (fluorescence PCR method) obtained medical device registration certificate

BreakingsMar 21 17:49